Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim. - Suppr | 超能文献

Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.

作者信息

Zimrin Ann, Chumsri Saranya

出版信息

Ann Hematol. 2013 Aug;92(8):1145-6. doi: 10.1007/s00277-013-1677-5. Epub 2013 Jan 18.

DOI:10.1007/s00277-013-1677-5

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.

Ann Hematol. 2013 Aug;92(8):1145-6. doi: 10.1007/s00277-013-1677-5. Epub 2013 Jan 18.

2

[Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].[特比澳用于既往接受过罗米司亭治疗的慢性免疫性血小板减少症患者]

Farm Hosp. 2013 May-Jun;37(3):265-6. doi: 10.7399/FH.2013.37.3.548.

3

Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.促血小板生成素受体激动剂用于准备接受脾切除术的成人免疫性血小板减少症患者：一项回顾性观察性 GIMEMA 研究的结果。

Am J Hematol. 2016 May;91(5):E293-5. doi: 10.1002/ajh.24341. Epub 2016 Apr 4.

4

Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.罗米司亭在艾曲泊帕耐药或不耐受的免疫性血小板减少症患者中的安全性和有效性。

Br J Haematol. 2013 Oct;163(2):286-9. doi: 10.1111/bjh.12483. Epub 2013 Jul 17.

5

The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).血小板生成素受体激动剂（TPO-RAs）在免疫性血小板减少症（ITP）中的应用：普利亚血液学网络（REP）的一项“真实生活”回顾性多中心经验。

Ann Hematol. 2016 Jan;95(2):239-44. doi: 10.1007/s00277-015-2556-z. Epub 2015 Nov 24.

6

Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.血小板生成素受体激动剂治疗系统性红斑狼疮相关难治性免疫性血小板减少症的疗效

J Rheumatol. 2014 Sep;41(9):1895-6. doi: 10.3899/jrheum.140080.

7

Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.免疫性血小板减少症（ITP）中血小板生成素受体激动剂（TPO-RAs）的序贯治疗：我们中心的经验

Ann Hematol. 2017 Mar;96(3):507-508. doi: 10.1007/s00277-016-2896-3. Epub 2016 Dec 15.

8

Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.在接受包括罗米司亭在内的多种治疗后，艾曲泊帕成功治疗免疫性血小板减少症。

Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s151-2. doi: 10.2450/2013.0135-13. Epub 2013 Oct 3.

9

Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim.用罗米司亭成功治疗艾曲泊帕耐药的难治性免疫性血小板减少症。

Int J Hematol. 2013 Feb;97(2):291-3. doi: 10.1007/s12185-012-1253-0. Epub 2012 Dec 29.

10

What is publication? The case of eltrombopag.什么是发表？以艾曲泊帕为例。

Lancet. 2011 Jan 29;377(9763):360-1. doi: 10.1016/S0140-6736(11)60024-X.

引用本文的文献

1

Metastatic Breast Cancer with Extensive Osseous Metastasis Presenting with Symptomatic Immune Thrombocytopenic Purpura and Anemia: A Case Report and Review of the Literature.广泛骨转移的转移性乳腺癌伴症状性免疫性血小板减少性紫癜和贫血：病例报告及文献复习

Case Rep Oncol. 2015 Jun 5;8(2):256-63. doi: 10.1159/000431213. eCollection 2015 May-Aug.

2

The biology of thrombopoietin and thrombopoietin receptor agonists.血小板生成素及其受体激动剂的生物学特性。

Int J Hematol. 2013 Jul;98(1):10-23. doi: 10.1007/s12185-013-1382-0. Epub 2013 Jul 3.